Perspective Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Perspective Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Jun 30, 2022 | $2.51M | Sep 28, 2022 |
| FY2022 | Mar 31, 2022 | $2.91M | Sep 28, 2022 |
| FY2022 | Dec 31, 2021 | $2.82M | Sep 28, 2022 |
| FY2022 | Sep 30, 2021 | $2.56M | Sep 28, 2022 |
| FY2022 | Jun 30, 2021 | $2.71M | Sep 28, 2022 |
| FY2022 | Mar 31, 2021 | $2.60M | Sep 28, 2022 |
| FY2022 | Dec 31, 2020 | $2.36M | Sep 28, 2022 |
| FY2022 | Sep 30, 2020 | $2.38M | Sep 28, 2022 |
| FY2021 | Jun 30, 2020 | $2.28M | Sep 27, 2021 |
| FY2021 | Mar 31, 2020 | $2.88M | Sep 27, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $1.43M | Mar 28, 2024 |
| FY2023 | Dec 31, 2022 | $0 | Mar 28, 2024 |
| FY2022 | Jun 30, 2022 | $926.0K | Sep 28, 2022 |
| FY2022 | Mar 31, 2022 | $1.44M | Sep 28, 2022 |
| FY2022 | Dec 31, 2021 | $1.22M | Sep 28, 2022 |
| FY2022 | Sep 30, 2021 | $1.03M | Sep 28, 2022 |
| FY2022 | Jun 30, 2021 | $1.35M | Sep 28, 2022 |
| FY2022 | Mar 31, 2021 | $1.36M | Sep 28, 2022 |
| FY2022 | Dec 31, 2020 | $1.17M | Sep 28, 2022 |
| FY2022 | Sep 30, 2020 | $1.25M | Sep 28, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($103.12M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($79.28M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($46.51M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($7.34M) | Mar 28, 2024 |
| FY2022 | Jun 30, 2022 | ($2.08M) | Sep 28, 2022 |
| FY2022 | Mar 31, 2022 | ($1.35M) | Sep 28, 2022 |
| FY2022 | Dec 31, 2021 | ($1.60M) | Sep 28, 2022 |
| FY2022 | Sep 30, 2021 | ($2.24M) | Sep 28, 2022 |
| FY2022 | Jun 30, 2021 | ($1.06M) | Sep 28, 2022 |
| FY2022 | Mar 31, 2021 | ($745.0K) | Sep 28, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($113.56M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($90.89M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($40.94M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($5.62M) | Mar 28, 2024 |
| FY2023 | Jun 30, 2022 | ($6.42M) | Mar 28, 2024 |
| FY2022 | Jun 30, 2021 | ($3.45M) | Sep 28, 2022 |
| FY2022 | Jun 30, 2020 | ($3.48M) | Sep 28, 2022 |
| FY2021 | Jun 30, 2019 | ($5.25M) | Sep 27, 2021 |
| FY2020 | Jun 30, 2018 | ($6.73M) | Sep 25, 2020 |
| FY2019 | Jun 30, 2017 | ($6.31M) | Sep 27, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $84.22M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $41.64M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $21.31M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $468.0K | Mar 28, 2024 |
| FY2023 | Jun 30, 2022 | $850.0K | Mar 28, 2024 |
| FY2022 | Jun 30, 2021 | $1.43M | Sep 28, 2022 |
| FY2022 | Jun 30, 2020 | $1.13M | Sep 28, 2022 |
| FY2021 | Jun 30, 2019 | $1.47M | Sep 27, 2021 |
| FY2020 | Jun 30, 2018 | $1.75M | Sep 25, 2020 |
| FY2019 | Jun 30, 2017 | $965.0K | Sep 27, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($82.48M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($18.29M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($36.91M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($6.09M) | Mar 28, 2024 |
| FY2023 | Jun 30, 2022 | ($7.71M) | Mar 28, 2024 |
| FY2022 | Jun 30, 2021 | ($2.84M) | Sep 28, 2022 |
| FY2022 | Jun 30, 2020 | ($3.64M) | Sep 28, 2022 |
| FY2021 | Jun 30, 2019 | ($5.05M) | Sep 27, 2021 |
| FY2020 | Jun 30, 2018 | ($5.71M) | Sep 25, 2020 |
| FY2019 | Jun 30, 2017 | ($5.71M) | Sep 27, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.75M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $54.41M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $1.07M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $151.0K | Mar 28, 2024 |
| FY2023 | Jun 30, 2022 | $266.0K | Mar 28, 2024 |
| FY2022 | Jun 30, 2021 | $381.0K | Sep 28, 2022 |
| FY2022 | Jun 30, 2020 | $273.0K | Sep 28, 2022 |
| FY2021 | Jun 30, 2019 | $444.0K | Sep 27, 2021 |
| FY2020 | Jun 30, 2018 | $337.0K | Sep 25, 2020 |
| FY2019 | Jun 30, 2017 | $549.0K | Sep 27, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $266.97M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $341.10M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $97.89M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $58.09M | Mar 28, 2024 |
| FY2022 | Jun 30, 2022 | $64.44M | Sep 28, 2022 |
| FY2022 | Jun 30, 2021 | $70.42M | Sep 28, 2022 |
| FY2021 | Jun 30, 2020 | $8.70M | Sep 27, 2021 |
| FY2020 | Jun 30, 2019 | $9.42M | Sep 25, 2020 |
| FY2019 | Jun 30, 2018 | $7.46M | Sep 27, 2019 |
| FY2018 | Jun 30, 2017 | $12.27M | Sep 26, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $59.94M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $50.43M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $22.71M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $3.45M | Mar 28, 2024 |
| FY2022 | Jun 30, 2022 | $3.16M | Sep 28, 2022 |
| FY2022 | Jun 30, 2021 | $3.01M | Sep 28, 2022 |
| FY2021 | Jun 30, 2020 | $2.98M | Sep 27, 2021 |
| FY2020 | Jun 30, 2019 | $1.74M | Sep 25, 2020 |
| FY2019 | Jun 30, 2018 | $2.43M | Sep 27, 2019 |
| FY2018 | Jun 30, 2017 | $1.67M | Sep 26, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $207.03M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $290.67M | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | $75.18M | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | $54.64M | Mar 28, 2025 |
| FY2023 | Jun 30, 2022 | $61.28M | Mar 28, 2024 |
| FY2023 | Jun 30, 2021 | $67.41M | Mar 28, 2024 |
| FY2022 | Jun 30, 2020 | $5.72M | Sep 28, 2022 |
| FY2022 | Jun 30, 2019 | $7.68M | Sep 28, 2022 |
| FY2021 | Jun 30, 2018 | $5.03M | Sep 27, 2021 |
| FY2020 | Jun 30, 2017 | $10.60M | Sep 25, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $0 | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $24.06M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Mar 28, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($334.84M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($231.72M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($152.44M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($105.93M) | Mar 28, 2024 |
| FY2022 | Jun 30, 2022 | ($98.60M) | Sep 28, 2022 |
| FY2022 | Jun 30, 2021 | ($91.33M) | Sep 28, 2022 |
| FY2021 | Jun 30, 2020 | ($87.94M) | Sep 27, 2021 |
| FY2020 | Jun 30, 2019 | ($84.49M) | Sep 25, 2020 |
| FY2019 | Jun 30, 2018 | ($79.35M) | Sep 27, 2019 |
| FY2018 | Jun 30, 2017 | ($72.60M) | Sep 26, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $30.63M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $61.58M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $9.24M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $20.99M | Mar 28, 2024 |
| FY2023 | Jun 30, 2022 | $55.89M | Mar 28, 2024 |
| FY2022 | Jun 30, 2021 | $63.83M | Sep 28, 2022 |
| FY2022 | Jun 30, 2020 | $2.39M | Sep 28, 2022 |
| FY2021 | Jun 30, 2019 | $5.33M | Sep 27, 2021 |
| FY2020 | Jun 30, 2018 | $2.60M | Sep 25, 2020 |
| FY2019 | Jun 30, 2017 | $5.93M | Sep 27, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.63M | Mar 16, 2026 |
| FY2024 | Dec 31, 2024 | $1.68M | Mar 28, 2025 |
| FY2023 | Dec 31, 2023 | $1.73M | Mar 28, 2024 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 28, 2024 |
| FY2022 | Jun 30, 2022 | 0 | Sep 28, 2022 |
| FY2022 | Mar 31, 2022 | 0 | Sep 28, 2022 |
| FY2022 | Dec 31, 2021 | 0 | Sep 28, 2022 |
| FY2022 | Sep 30, 2021 | 0 | Sep 28, 2022 |
| FY2022 | Jun 30, 2021 | 0 | Sep 28, 2022 |
| FY2022 | Mar 31, 2021 | 0 | Sep 28, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 28, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 74.34M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | 70.67M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | 28.18M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | 142.11M | Mar 28, 2024 |
| FY2022 | Jun 30, 2022 | 142.04M | Sep 28, 2022 |
| FY2022 | Jun 30, 2021 | 141.92M | Sep 28, 2022 |
| FY2021 | Jun 30, 2020 | 68.90M | Sep 27, 2021 |
| FY2020 | Jun 30, 2019 | 67.39M | Sep 25, 2020 |
| FY2019 | Jun 30, 2018 | 56.33M | Sep 27, 2019 |
| FY2018 | Jun 30, 2017 | 55.02M | Sep 26, 2018 |